Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12659
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Louis, William J | en |
dc.contributor.author | Drummer, Olaf H | en |
dc.contributor.author | Howes, L G | en |
dc.date.accessioned | 2015-05-16T02:23:10Z | |
dc.date.available | 2015-05-16T02:23:10Z | |
dc.date.issued | 1989-05-16 | en |
dc.identifier.citation | Clinical and Experimental Hypertension. Part A, Theory and Practice; 11(5-6): 1075-83 | en |
dc.identifier.govdoc | 2571433 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12659 | en |
dc.description.abstract | Antihypertensive drugs that interact with adrenoceptors have certain advantages and disadvantages (on the treatment of hypertension). Alpha-1 antagonists such as prazosin have favorable effects on plasma lipids but may produce excessive postural falls in blood pressure, particularly following the initial dose. Recently developed alpha-1 antagonists (doxazosin, terazosin) have longer durations of action than prazosin, allowing less frequent administration. Beta blockers may be cardioprotective but in contrast to alpha-1 antagonists tend to have adverse effects on plasma lipids. Drugs with combined beta and alpha-1 blocking activity such as labetalol have favorable metabolic effects but postural hypotension remains a problem. Recently developed drugs with different alpha-1/beta blocking ratios that differ from labetalol may prove to be more popular clinically. Several beta blockers with vasodilator activity which is not due to alpha-1 blockade have also been developed. These drugs appear to have favorable metabolic effects similar to drugs with alpha-1 blocking activity, but do not cause postural hypotension. | en |
dc.language.iso | en | en |
dc.subject.other | Adrenergic alpha-Antagonists.therapeutic use | en |
dc.subject.other | Adrenergic beta-Antagonists.therapeutic use | en |
dc.subject.other | Antihypertensive Agents.adverse effects.therapeutic use | en |
dc.subject.other | Humans | en |
dc.subject.other | Hypertension.blood.complications.drug therapy | en |
dc.subject.other | Lipids.blood | en |
dc.subject.other | Vascular Diseases.etiology.prevention & control | en |
dc.subject.other | Vasodilator Agents.therapeutic use | en |
dc.title | Alpha blockers and vasodilating beta blockers--influence on factors involved in the pathogenesis of vascular disease in patients with hypertension. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Clinical and experimental hypertension. Part A, Theory and practice | en |
dc.identifier.affiliation | Department of Clinical Pharmacology & Therapeutics, Austin Hospital, Heidelberg, Victoria, Australia | en |
dc.description.pages | 1075-83 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/2571433 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Louis, William J | |
item.fulltext | No Fulltext | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Clinical Pharmacology and Therapeutics | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.